StreetInsider.com News Articles

Form 424B3 Eloxx Pharmaceuticals,

Thu, 22 Oct 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20261022/27218296.html

Form 8-K Eloxx Pharmaceuticals, For: Oct 19

Thu, 22 Oct 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20261022/27218289.html

Form 4 Eloxx Pharmaceuticals, For: Oct 19 Filed by: Germano Geno J

Wed, 21 Oct 2026 19:33:00 -0400

si-local-file:///var/storage/secattach/20261021/27217521.html

Form 3 Eloxx Pharmaceuticals, For: Oct 19 Filed by: Germano Geno J

Wed, 21 Oct 2026 19:32:00 -0400

si-local-file:///var/storage/secattach/20261021/27217520.html

Eloxx finalizes Phase 2 ADPKD trial design, names new CMO

Tue, 20 Oct 2026 09:32:46 -0400

Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) has finalized the design of its EXPRESS Phase 2 global clinical trial evaluating exaluren in patients with nonsense-mutation autosomal dominant polycystic kidney disease (ADPKD), and appointed T.R. Srinivas, M.D., as Senior Vice President and Chief Medical Officer.

The EXPRESS trial will enroll approximately 60 adults with genetically confirmed PKD1 or PKD2 nonsense mutations, randomized 1:1 to receive exaluren or placebo for 52 weeks. The primary endpoint is the annualized rate of change in height-adjusted total kidney volume (htTKV), measured by MRI at baseline and at weeks 28, 36, and 52. First patient dosing is expected in

Eloxx finalizes Phase 2 ADPKD trial design, names new CMO

Tue, 20 Oct 2026 09:32:46 -0400

Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D., Chief Medical Officer

Tue, 20 Oct 2026 09:31:00 -0400

EXPRESS Phase 2 design finalized: 52 weeks of dosing of approximately 60 patients randomized 1:1 to exaluren or placebo, with annualized htTKV growth as the primary endpoint
Substantial, durable htTKV effect could support Breakthrough Therapy Designation; FDA also lists htTKV as a potential surrogate endpoint for accelerated

Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D., Chief Medical Officer

Tue, 20 Oct 2026 09:31:00 -0400

EXPRESS Phase 2 design finalized: 52 weeks of dosing of approximately 60 patients randomized 1:1 to exaluren or placebo, with annualized htTKV growth as the primary endpoint

Substantial, durable htTKV effect could support Breakthrough Therapy Designation; FDA also lists htTKV as a potential surrogate endpoint for accelerated

Eloxx Pharmaceuticals adds former Pfizer executive to its board

Mon, 19 Oct 2026 16:05:41 -0400

Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) announced the appointment of Geno Germano to its Board of Directors, effective Oct. 19, 2026, according to a company press release.

Germano brings more than 35 years of biopharmaceutical experience, including roles at Pfizer Inc., where he served as Group President of the Global Innovative Pharmaceutical business, overseeing an approximately $14 billion portfolio and the late-stage development of more than a dozen drug candidates across five therapeutic areas.

He also previously served as President and Chief Executive Officer of Elucida Oncology, Inc. and as President of Intrexon Corporation, now known as Precigen, Inc. Earlier in his career,

Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors

Mon, 19 Oct 2026 16:05:00 -0400

Mr. Germano brings more than 35 years of biopharmaceutical leadership experience, including as Group President of Pfizer's Global Innovative Pharmaceutical business

Extensive public company board experience, including current service as Chairman of Entera Bio and as a director of Precision BioSciences

Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors

Mon, 19 Oct 2026 16:05:00 -0400

Mr. Germano brings more than 35 years of biopharmaceutical leadership experience, including as Group President of Pfizer's Global Innovative Pharmaceutical business

Extensive public company board experience, including current service as Chairman of Entera Bio and as a director of Precision BioSciences

Cantor Fitzgerald Starts Eloxx Pharma (ELOX) at Overweight

Thu, 15 Oct 2026 06:32:49 -0400

Cantor Fitzgerald initiates coverage on Eloxx Pharma (NASDAQ: ELOX) with a Overweight rating.
For an analyst ratings summary and ratings history on Eloxx Pharma click here. For more ratings news on Eloxx Pharma click here.
Shares of Eloxx Pharma closed at $12.21 yesterday.

Form EFFECT Eloxx Pharmaceuticals,

Mon, 21 Sep 2026 06:08:00 -0400
si-local-file:///var/storage/secattach/20260921/27082586.html

Leerink Starts Eloxx Pharma (ELOX) at Outperform

Fri, 18 Sep 2026 06:07:09 -0400

Leerink analyst Joseph Schwartz initiates coverage on Eloxx Pharma (NASDAQ: ELOX) with a Outperform rating and a price target of $32.00.
For an analyst ratings summary and ratings history on Eloxx Pharma click here. For more ratings news on Eloxx Pharma click here.
Shares of Eloxx Pharma closed at $17.55 yesterday.

Form S-1 Eloxx Pharmaceuticals,

Fri, 11 Sep 2026 17:29:00 -0400
si-local-file:///var/storage/secattach/20260911/27053755.html

Eloxx doses first patients in Phase 2b Alport syndrome trial

Fri, 11 Sep 2026 07:30:33 -0400

Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) announced that the first two patients have been dosed in the EXACT Study, a Phase 2b clinical trial evaluating exaluren in patients with nonsense mutation Alport syndrome (NMAS), according to a company press release dated Sept. 11, 2026.

The EXACT Study is a randomized, placebo-controlled, delayed-start, global trial enrolling 24 patients with NMAS caused by nonsense mutations in the COL4A3, COL4A4, or COL4A5 genes. The initial 16-week placebo-controlled portion carries a primary efficacy endpoint focused on structural changes in podocyte foot process effacement, as measured by change in filtration slit density in kidney biopsies. Topline data

Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome

Fri, 11 Sep 2026 07:30:00 -0400

First two patients dosed in the EXACT study

Topline data from the initial 16-week placebo-controlled portion of the study expected mid-2027; final readout expected by the end of 2027

Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome

Fri, 11 Sep 2026 07:30:00 -0400

First two patients dosed in the EXACT study

Topline data from the initial 16-week placebo-controlled portion of the study expected mid-2027; final readout expected by the end of 2027

Lucid Capital Markets Starts Eloxx Pharma (ELOX) at Buy

Thu, 20 Aug 2026 06:05:52 -0400
(Updated - August 20, 2026 6:05 AM EDT)
Lucid Capital Markets analyst Dev Prasad initiates coverage on Eloxx Pharma (NASDAQ: ELOX) with a Buy rating and a price target of $38.00.
The analyst comments "We initiate coverage of Eloxx Pharmaceuticals (ELOX) with a Buy rating and a $38 price target, reflecting an attractive risk/reward profile ahead of the mid-2027 EXACT Phase 2b readout in nonsense-mutation Alport syndrome (NMAS). The lead asset, exaluren, is designed to restore full-length protein production in diseases caused by nonsense mutations. Preliminary Phase 2a data in three NMAS patients showed a mean 72% increase in collagen IV α3/α4

Lucid Capital Markets Starts Eloxx Pharma (ELOX) at Buy

Thu, 20 Aug 2026 06:05:52 -0400
(Updated - August 20, 2026 6:05 AM EDT)
Lucid Capital Markets analyst Dev Prasad initiates coverage on Eloxx Pharma (NASDAQ: ELOX) with a Buy rating and a price target of $38.00.
The analyst comments "We initiate coverage of Eloxx Pharmaceuticals (ELOX) with a Buy rating and a $38 price target, reflecting an attractive risk/reward profile ahead of the mid-2027 EXACT Phase 2b readout in nonsense-mutation Alport syndrome (NMAS). The lead asset, exaluren, is designed to restore full-length protein production in diseases caused by nonsense mutations. Preliminary Phase 2a data in three NMAS patients showed a mean 72% increase in collagen IV α3/α4

Lucid Capital Markets Starts Eloxx Pharma (ELOX) at Buy

Thu, 20 Aug 2026 06:05:52 -0400
(Updated - August 20, 2026 6:05 AM EDT)
Lucid Capital Markets analyst Dev Prasad initiates coverage on Eloxx Pharma (NASDAQ: ELOX) with a Buy rating and a price target of $38.00.
The analyst comments "We initiate coverage of Eloxx Pharmaceuticals (ELOX) with a Buy rating and a $38 price target, reflecting an attractive risk/reward profile ahead of the mid-2027 EXACT Phase 2b readout in nonsense-mutation Alport syndrome (NMAS). The lead asset, exaluren, is designed to restore full-length protein production in diseases caused by nonsense mutations. Preliminary Phase 2a data in three NMAS patients showed a mean 72% increase in collagen IV α3/α4

Lucid Capital Markets Starts Eloxx Pharma (ELOX) at Buy

Thu, 20 Aug 2026 06:05:52 -0400
(Updated - August 20, 2026 6:05 AM EDT)
Lucid Capital Markets analyst Dev Prasad initiates coverage on Eloxx Pharma (NASDAQ: ELOX) with a Buy rating and a price target of $38.00.
The analyst comments "We initiate coverage of Eloxx Pharmaceuticals (ELOX) with a Buy rating and a $38 price target, reflecting an attractive risk/reward profile ahead of the mid-2027 EXACT Phase 2b readout in nonsense-mutation Alport syndrome (NMAS). The lead asset, exaluren, is designed to restore full-length protein production in diseases caused by nonsense mutations. Preliminary Phase 2a data in three NMAS patients showed a mean 72% increase in collagen IV α3/α4

Form SCHEDULE 13G Eloxx Pharmaceuticals, Filed by: Samsara BioCapital, L.P.

Fri, 14 Aug 2026 16:54:00 -0400
si-local-file:///var/storage/secattach/20260814/26932275.html

Form SCHEDULE 13G Eloxx Pharmaceuticals, Filed by: Samsara BioCapital, L.P.

Fri, 14 Aug 2026 16:54:00 -0400
si-local-file:///var/storage/secattach/20260814/26932275.html

Form SCHEDULE 13G Eloxx Pharmaceuticals, Filed by: Nantahala Capital Management, LLC

Fri, 14 Aug 2026 16:44:00 -0400
si-local-file:///var/storage/secattach/20260814/26932028.html